Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 84.14% | 62.23% | 59.76% | 48.76% | 48.22% |
| Total Depreciation and Amortization | 4.10% | 0.19% | 19.20% | 71.57% | 200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -183.63% | -31.66% | 95.84% | 41.50% | -11.05% |
| Change in Net Operating Assets | -238.21% | 103.81% | -266.17% | -2,606.02% | 464.25% |
| Cash from Operations | 52.42% | 73.75% | 67.70% | 52.22% | 55.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.89% | -4.41% | -22.18% | -73.51% | -201.74% |
| Issuance of Common Stock | 5,406.57% | -38.81% | -87.71% | -87.71% | -87.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -99.96% | -100.00% | -100.00% | -100.00% |
| Cash from Financing | 6,114.76% | -63.06% | -89.17% | -89.22% | -89.24% |
| Foreign Exchange rate Adjustments | 2,113.38% | 124.78% | -198.67% | -219.05% | -228.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,203.99% | 78.99% | -377.85% | -103.15% | -6.16% |